CD7 and acute lymphoblastic leukemia: Thus, V‐HAG may serve as the first‐line salvage therapy for patients with refractory/relapsed ETP‐ALL, while CD7‐directed CAR‐T therapy could be considered a supplementary treatment for those who develop resistance to the V‐HAG regimen [49].